Analyst Leah Cann works at BROOKLINE and is focused on the Healthcare sector with 130 price targets and ratings documented since 2016 spanning on 14 stocks. Previously, Leah Cann worked at OPPENHEIMER. Analyst's average stock valuation to be materialised ratio is 41.67% with an average time for price targets to be met of 191.5 days.
Most recent stock forecast was given on MRNA, Moderna, Inc at 22-Jun-2022.
Leah Cann best performing recommendations are on SYRS.
The best stock recommendation documented was for MRNA (MODERNA, INC) at 11/25/2020. The price target of $164 was fulfilled within 13 days with a profit of $54.82 (50.21%) receiving and performance score of 38.62.
Average potential price target upside
Currently, out of the existing stock ratings of Leah Cann - 2708 which are a Buy (98.76%), 34 which are a Hold (1.24%)
Analyst name
Rating
Current price target
Potential distance
Previous price target
Date
Price targets met ratio
Average potential upside
Average time for PT to be met
Performance score
Hold
265
$26.52 (11.12%)
275
16 days ago
3/7 (42.86%)
$29.16 (12.54%)
377
Hold
260
$21.52 (9.02%)
280
1 months 16 days ago
26/27 (96.3%)
$42.93 (26.07%)
638
Sell
230
$-8.48 (-3.56%)
240
1 months 27 days ago
16/16 (100%)
$10.47 (7.10%)
219
Hold
253
$14.52 (6.09%)
276
1 months 27 days ago
16/18 (88.89%)
$34.97 (17.12%)
390
Buy
294
$55.52 (23.28%)
312
1 months 27 days ago
18/22 (81.82%)
$41.89 (18.96%)
533
